Skip to main content
. 2017 Aug 21;7:8944. doi: 10.1038/s41598-017-09387-8

Figure 1.

Figure 1

Protein synthesis inhibitors inversely regulate oncogenic H-ras and K-ras nanoclustering. (A,B) Schematic illustration of the nanoclustering-FRET assay. FRET is increased due to the formation of transiently immobile signalling complexes, which lead to nanoscale clustering of H-ras (A) or K-ras (B) in the plasma membrane. (C,D) Nanoclustering-FRET analysis in HEK cells co-expressing mGFP- and mCherry-tagged (C) H-rasG12V or (D) K-rasG12V. Cells were treated for 24 h with DMSO control, or 2 μM of the protein synthesis inhibitors diacetoxyscirpenol and emetine, or 0.4 μM of the proteasome inhibitor bortezomib. The numbers in the bars indicate the number of analyzed cells (mean ± SEM, n = 3). Statistical significance levels are annotated as *p < 0.05; **p < 0.01; ****p < 0.0001.